Erba, H., Wang, E., Issa, G., Altman, J., Montesinos, P., DeBotton, S., … Fathi, A. (2023). Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 23, pp. S304–S305).

Erba, Harry, Eunice Wang, Ghayas Issa, Jessica Altman, Pau Montesinos, Stephane DeBotton, Roland Walter, et al. “Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 23:S304–5, 2023.

Erba H, Wang E, Issa G, Altman J, Montesinos P, DeBotton S, et al. Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023. p. S304–5.

Erba, Harry, et al. “Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 23, 2023, pp. S304–05.

Erba H, Wang E, Issa G, Altman J, Montesinos P, DeBotton S, Walter R, Pettit K, Strickland S, Patnaik M, Kremyanskaya M, Baer M, Foran J, Schiller G, Ades L, Heiblig M, Berthon C, Grembecka J, Cierpicki T, Clegg B, Peterlin P, Rodriguez Arboli E, Salamero O, Papayannidis C, Nie K, Ahsan JM, Tabachri M, Corum D, Leoni M, Dale S, Fathi A. Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023. p. S304–S305.